Drug intelligence / Profile preview

Cevipabulin

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Cevipabulin is a synthetic, water-soluble small molecule tubulin-binding agent with potential antineoplastic activity. It binds at the vinca-binding site on tubulin but acts similarly to taxane-site binding agents by enhancing tubulin polymerization rather than inducing depolymerization. This disruption of microtubule dynamics inhibits cell division and reduces cellular growth, making it effective against various tumors including those resistant to paclitaxel and vincristine. Cevipabulin is stable, water-soluble, and can be administered intravenously or orally. It was developed for cancer treatment and has been studied in clinical trials up to phase II[1][3][7][10].

Other names: cevipabulinaCevipabulin fumarate

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on Cevipabulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cevipabulin.

Explore the full profile